Maarten van der Doelen

Actinium-225 labeled PSMA radioligand therapy in mCRPC patients

Supplementary table 4. Outcomes of the Xerostomia Inventory.

End of therapy (n=7)

Follow-up 12 months (n=5)

Follow-up 18 months (n=3)

Baseline (n=7)

Xerostomia Inventory a

1. I sip liquids to aid in swallowing food

1 [1-2]

3 [1-4]

3 [3-4]

3 NA

2. My mouth feels dry when eating a meal

1 [1-2]

3 [2-4]

3 [1.5-4]

3 NA

2

3. I get up at night to drink

1 [1-3]

2 [2-3]

2 [1.5-2.5]

2 NA

4. My mouth feels dry

1 [1-2]

4 [3-5]

4 [2.5-4]

4 NA

5. I have difficulty in eating dry foods

1 [1-2]

5 [3-5]

4 [3-5]

4 NA

6. I suck sweets or lollies to relieve dry mouth

1 [1-2]

3 [1-5]

2 [1.5-3]

2 NA

7. I have difficulties swallowing certain foods

1 [1-2]

5 [2-5]

2 [1.5-4.5]

3 NA

8. The skin of my face feels dry

2 [1-2]

1 [1-2]

2 [1.5-2]

2 NA

9. My eyes feel dry

1 [1-2]

2 [1-4]

3 [1-.3.5]

2 NA

10. My lips feel dry

2 [1-2]

2 [1-4]

3 [2.5-3.5]

3 NA

11. The inside of my nose feels dry

1 [1-2]

1 [1-3]

2 [1-2]

2 NA

Total score

16 [11-24]

27 [23-39]

28 [20-42]

29 NA

P 0.018

P 0.043

Data are presented as median scores [IQR]. Scores of the xerostomia inventory per item: 1=never; 2=hardly ever; 3=occasionally; 4=frequently; 5=always. NA = not applicable. a Higher scores indicate worse symptoms/aspects.

49